Catalyst Pharmaceuticals has sued the Food and Drug Administration over exclusivity rights for its rare disease drug, Firdapse. In May, Jacobus Pharmaceuticals’ rival drug, Ruzurgi, was approved, providing patients with a more affordable treatment option at $175,200 annually in comparison to $375,000 for Catalyst’s drug. Catalyst is arguing that the FDA was influenced by the political debate about high drug prices. (Reuters)

Facebook has started rolling out a tool for blood donations. Once a user signs up, he or she will receive notifications when a local blood bank needs certain types of blood. The tool, launched outside the U.S. in 2017, is available in some American cities before its nationwide rollout in the coming months. (CNBC)

Here’s a big question for all consumer healthcare marketers: how do you deal with trolls on social media? Share your best strategies and practices using #DontTrollOnMe on LinkedIn, Twitter or Instagram or by emailing before 5 p.m. EST on June 26, and we’ll compile a list to share. (MM&M)

WPP CEO Mark Read has said the sale of its stake in Kantar is on track. Bain Capital, Apollo, Platinum and an undisclosed prospective buyer are in the final stages of bidding. The data analytics firm generates 15% of WPP’s sales. (Reuters)

The cost of AstraZeneca’s new headquarters has reached $956 million, double the original estimate. This price tag makes it one of the most expensive corporate buildings in the U.K. After delays, the project is expected to be ready by 2020. (Endpoints)